Total Payments
$1.0M
2024 Payments
$96,039
Companies
60
Transactions
3,378
Medicare Patients
4,547
Medicare Billing
$295,239
Payment Breakdown by Category
Other$731,599 (72.6%)
Travel$178,607 (17.7%)
Food & Beverage$53,987 (5.4%)
Consulting$35,711 (3.5%)
Research$7,165 (0.7%)
Education$275.44 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $672,586 | 501 | 66.8% |
| Travel and Lodging | $178,607 | 568 | 17.7% |
| Honoraria | $59,013 | 33 | 5.9% |
| Food and Beverage | $53,987 | 2,230 | 5.4% |
| Consulting Fee | $35,711 | 17 | 3.5% |
| Unspecified | $7,165 | 6 | 0.7% |
| Education | $275.44 | 23 | 0.0% |
Payments by Type
General
$1.0M
3,372 transactions
Research
$7,165
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $476,203 | 1,104 | $0 (2024) |
| Novo Nordisk Inc | $186,941 | 402 | $0 (2024) |
| GRT US Holding, Inc. | $86,517 | 155 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $52,109 | 127 | $0 (2020) |
| Amgen Inc. | $48,809 | 166 | $0 (2024) |
| Corcept Therapeutics | $30,411 | 109 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $29,932 | 105 | $0 (2024) |
| Averitas Pharma Inc. | $27,088 | 62 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $24,032 | 125 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $9,361 | 97 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $96,039 | 357 | Lilly USA, LLC ($60,261) |
| 2023 | $100,449 | 412 | Lilly USA, LLC ($54,219) |
| 2022 | $176,161 | 512 | GRT US Holding, Inc. ($85,666) |
| 2021 | $60,637 | 286 | Novo Nordisk Inc ($29,155) |
| 2020 | $71,584 | 324 | Lilly USA, LLC ($36,032) |
| 2019 | $161,853 | 524 | Lilly USA, LLC ($97,532) |
| 2018 | $129,836 | 429 | Lilly USA, LLC ($79,513) |
| 2017 | $210,784 | 534 | Lilly USA, LLC ($84,419) |
All Payment Transactions
3,378 individual payment records from CMS Open Payments — Page 1 of 136
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: Diabetes Care | ||||||
| 12/20/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $26.36 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 12/11/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: Endocrinology | ||||||
| 12/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: Cardio-renal | ||||||
| 12/10/2024 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: Diabetes Care | ||||||
| 12/10/2024 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: Diabetes Care | ||||||
| 12/09/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $23.26 | General |
| Category: Diabetes | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/02/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 11/21/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: Diabetes | ||||||
| 11/20/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: Diabetes | ||||||
| 11/20/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $4.92 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 11/19/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | In-kind items and services | $1,995.00 | General |
| Category: Bone Health | ||||||
| 11/19/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: Durable Pump | ||||||
| 11/18/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Bone Health | ||||||
| 11/18/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: Bone Health | ||||||
| 11/14/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $91.58 | General |
| Category: Bone Health | ||||||
| 11/14/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Travel and Lodging | Cash or cash equivalent | $47.57 | General |
| Category: Diabetes | ||||||
| 11/13/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Travel and Lodging | Cash or cash equivalent | $46.90 | General |
| Category: Diabetes | ||||||
| 11/13/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $650.00 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $650.00 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $650.00 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $650.00 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: Cardio-renal | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $6,604 | 4 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $436.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 973 | 1,424 | $208,021 | $73,551 |
| 2022 | 7 | 1,055 | 1,551 | $217,469 | $79,817 |
| 2021 | 7 | 1,220 | 1,622 | $204,403 | $79,452 |
| 2020 | 8 | 1,299 | 1,696 | $171,911 | $62,419 |
Total Patients
4,547
Total Services
6,293
Medicare Billing
$295,239
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 286 | 541 | $94,675 | $35,143 | 37.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 524 | 670 | $73,700 | $28,186 | 38.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 56 | 56 | $14,896 | $4,921 | 33.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 60 | 60 | $10,200 | $2,954 | 29.0% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 47 | 97 | $14,550 | $2,347 | 16.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 590 | 850 | $93,500 | $38,374 | 41.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 226 | 364 | $63,695 | $24,964 | 39.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 69 | 69 | $18,354 | $6,310 | 34.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 75 | 75 | $12,750 | $4,323 | 33.9% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 45 | 138 | $20,700 | $3,513 | 17.0% |
| 64632 | Destruction of foot nerve | Office | 2022 | 13 | 18 | $4,770 | $1,370 | 28.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 37 | 37 | $3,700 | $962.85 | 26.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 563 | 836 | $91,960 | $37,474 | 40.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 294 | 342 | $37,620 | $17,461 | 46.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 65 | 77 | $12,225 | $5,290 | 43.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 51 | 60 | $10,500 | $4,588 | 43.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 74 | 74 | $12,580 | $4,206 | 33.4% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Facility | 2021 | 39 | 89 | $13,350 | $2,340 | 17.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 22 | 22 | $5,852 | $2,106 | 36.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 23 | 23 | $3,939 | $1,514 | 38.4% |
| 64632 | Destruction of nerve of foot | Facility | 2021 | 17 | 19 | $5,035 | $1,408 | 28.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $3,192 | $1,252 | 39.2% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 19 | 27 | $4,050 | $734.67 | 18.1% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 22 | 22 | $2,200 | $608.30 | 27.7% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 19 | 19 | $1,900 | $470.05 | 24.7% |
About Mark Borchelt, MD, FACE
Mark Borchelt, MD, FACE is a Endocrinology, Diabetes & Metabolism healthcare provider based in Gulfport, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1194776286.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mark Borchelt, MD, FACE has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $96,039 received in 2024. These payments were reported across 3,378 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($672,586).
As a Medicare-enrolled provider, Borchelt has provided services to 4,547 Medicare beneficiaries, totaling 6,293 services with total Medicare billing of $295,239. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location Gulfport, MS
- Active Since 05/13/2006
- Last Updated 06/14/2024
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1194776286
Products in Payments
- TRULICITY (Drug) $253,655
- MOUNJARO (Drug) $119,683
- Qutenza (Drug) $86,517
- Ozempic (Drug) $71,374
- INVOKANA (Drug) $52,035
- JARDIANCE (Drug) $45,285
- Tresiba (Drug) $35,866
- EVENITY (Biological) $33,550
- Korlym (Drug) $30,411
- Victoza (Drug) $29,699
- QUTENZA (Drug) $27,088
- FARXIGA (Drug) $26,056
- BAQSIMI (Drug) $21,939
- Prolia (Biological) $14,502
- Xultophy 100/3.6 (Drug) $13,783
- RYBELSUS (Drug) $12,271
- Rybelsus (Drug) $9,502
- JATENZO (Drug) $8,033
- SOLIQUA (Drug) $7,915
- BYDUREON (Drug) $3,840
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.